![](https://site-1991660.mozfiles.com/files/1991660/medium/Pipeline-ISOREA-2.jpg)
![](https://site-1991660.mozfiles.com/files/1991660/medium/Pipeline-ISOREA-2.jpg)
AD Risk Detection Kit (Gen.1)
Based on novel monoclonal antibody (world-wide patent application (PCT) submitted), the kit consists of two complementary ELISAs for reliable (>95% ) diagnostics of early dementia stages. Being recently tested on Shanghai cohort, the kit showed much superior performance compared to other blood biomarkers.
![](https://site-1991660.mozfiles.com/files/1991660/inlinepicturesbox/medium/77112211-a3637017054506c57122d51f176a91de.jpg)
Our ELISA kit contains:
A. In-house developed Monoclonal Antibody for isoAsp detection.
B. Aged HSA for complementary detection of natural anti-isoAsp antibodies in blood.
C. Associated generic secondary antibody, detection solution, buffer, and Maxi-sorbent ELISA plate; instruction manual.
Discovery & Background
- LC-MS/MS revealed LVNEVTEFAK peptide from a functionally important HSA domain to exhibit the highest deamidation rate in aged HSA.
- A novel monoclonal antibody (mAb) 1A3 generated against LVNEVTEFAK showed excellent specificity to isoAsp in HSA and no cross-reactivity with other aged proteins.
- Using indirect ELISA with chemiluminescence we have measured the range of isoAsp in HSA of healthy blood for the first time, determining the safe region being (0.7±0.3)%.
- We also discovered natural anti-isoAsp antibodies in blood, with their level being reduced in AD. Thus we developed another ELISA using artificially aged HSA as a bait.
- Combination of both ELISA results provides a >95% sensitivity in diagnostics of early dementia.
Find more information in our Publications.
![](https://site-1991660.mozfiles.com/files/1991660/inlinepicturesbox/medium/77112361-e624fbbdd0af86a5ed49ea77fd2913bb.jpg)